Abstract:Abstract Dengue virus (DENV) infection causes serious health problems in humans for which no drug is currently available. Recently, DENV NS2B-NS3 protease has been proposed as a primary target for anti-dengue drug discovery due to its important role in new virus particle formation by conducting DENV polyprotein cleavage. Triterpenoids from the medicinal fungus Ganoderma lucidum have been suggested as pharmacologically bioactive compounds and tested as anti-viral agents against various viral pathogens including human immunodeficiency virus. However, no reports are available concerning the anti-viral activity of triterpenoids from Ganoderma lucidum against DENV. Therefore, we employed a virtual screening approach to predict the functional triterpenoids from Ganoderma lucidum as potential inhibitors of DENV NS2B-NS3 protease, followed by an in vitro assay. From in silico analysis of twenty-two triterpenoids of Ganoderma lucidum , four triterpenoids, viz. Ganodermanontriol (−6.291 kcal/mol), Lucidumol A (−5.993 kcal/mol), Ganoderic acid C2 (−5.948 kcal/mol) and Ganosporeric acid A (−5.983 kcal/mol) were predicted to be viral protease inhibitors by comparison to reference inhibitor 1,8-Dihydroxy-4,5-dinitroanthraquinone (−5.377 kcal/mol). These results were further studied for binding affinity and stability using the molecular mechanics/generalized Born surface area method and Molecular Dynamics simulations, respectively. Also, in vitro viral infection inhibition suggested that Ganodermanontriol is a potent bioactive triterpenoid.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to discover whether triterpenoids in Ganoderma lucidum can be potential inhibitors against the NS2B - NS3 protease of dengue virus (DENV). Specifically, the research aims to identify candidate molecules among Ganoderma lucidum triterpenoids that can effectively inhibit the activity of DENV NS2B - NS3 protease through virtual screening and in vitro experiments, with the expectation of developing new drugs for dengue virus infection. ### Research Background - **Dengue virus (DENV)**: It belongs to the Flaviviridae family, is transmitted by mosquitoes, and can cause dengue hemorrhagic fever and dengue shock syndrome. Currently, there are no specific drugs. - **NS2B - NS3 protease**: It plays a crucial role in the DENV infection process and is responsible for the cleavage of the viral polyprotein, so it is considered as the main target for anti - dengue virus drug development. - **Ganoderma lucidum triterpenoids**: Ganoderma lucidum is a medicinal fungus, and its triterpenoids have multiple pharmacological activities, including antiviral activity. However, there have been no reports on the antiviral activity of these compounds against DENV. ### Research Objectives 1. **Virtual screening**: Predict the binding affinity between 22 triterpenoids in Ganoderma lucidum and DENV NS2B - NS3 protease through virtual screening. 2. **Molecular dynamics simulation**: Verify the binding stability of the screened compounds with the protease. 3. **In vitro experiments**: Further verify the inhibitory effect of the screened compounds on DENV through in vitro experiments. ### Main Results - **Virtual screening**: Four compounds with relatively high binding affinities were screened out from 22 triterpenoids, namely: - **Ganodermanontriol** (−6.291 kcal/mol) - **Lucidumol A** (−5.993 kcal/mol) - **Ganoderic acid C2** (−5.948 kcal/mol) - **Ganosporeric acid A** (−5.983 kcal/mol) - **Molecular dynamics simulation**: The binding of these four compounds with NS2B - NS3 protease is stable, especially Ganodermanontriol shows the strongest binding affinity. - **In vitro experiments**: Ganodermanontriol shows significant anti - DENV activity in vitro experiments, and can reduce the virus titer by approximately 40% and 25% at concentrations of 50 μM and 25 μM respectively. ### Conclusion Based on the results of virtual screening, molecular dynamics simulation and in vitro experiments, Ganodermanontriol is determined as a potential anti - DENV drug candidate molecule and has the potential to be further developed into an antiviral drug derived from natural products.

Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease

The identification of active compounds in Ganoderma lucidum var. antler extract inhibiting dengue virus serine protease and its computational studies

Computational design and in vitro assay of lantadene-based novel inhibitors of NS3 protease of dengue virus

Identification of Antiviral Phytocompounds as Potential Anti‐Dengue Agents against DENV NS2B/NS3 Protease: An Integrated Molecular Modelling and Dynamics Approach

Anti-human immunodeficiency virus-1 protease activity of new lanostane-type triterpenoids from Ganoderma sinense.

Evaluation of Melongosides as Potential Inhibitors of NS2B-NS3 Activator-Protease of Dengue Virus (Serotype 2) by Using Molecular Docking and Dynamics Simulation Approach

exploration of potent flavonoids for dengue therapeutics

Discovery of Dengue Virus Ns4b Inhibitors

Insight into the in silico Study and Biological Evaluation of Curcumin Analogue Compounds as New Potential Inhibitors for Dengue DEN2 NS2B/NS3 Serine Protease

Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein.

Investigation of small molecules disrupting dengue virus assembly by inhibiting capsid protein and blocking RNA encapsulation

Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection

In silico homology modeling of dengue virus non-structural 4B (NS4B) protein and its molecular docking studies using triterpenoids

Investigating Lycotoxin-An1a (An1a), a defense antiviral peptide from Alopecosa nagpag venom as prospective anti-dengue agent against DENV-2 NS2B-NS3 protease

Phytochemicals of Different Medicinal Herbs as Potential Inhibitors Against Dengue Serotype 2 Virus: A Computational Approach

Identification of a Novel Inhibitor of Dengue Virus Protease through Use of a Virtual Screening Drug Discovery Web Portal

Computational identification of Vernonia cinerea-derived phytochemicals as potential inhibitors of nonstructural protein 1 (NSP1) in dengue virus serotype-2

Discovery of highly potent DENV NS2B-NS3 covalent inhibitors containing a phenoxymethylphenyl residue

Design, synthesis and biological activity evaluation of novel allosteric inhibitors of the DENV NS2B–NS3 protease

Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease.

In Silico-Based Identification of Natural Inhibitors from Traditionally Used Medicinal Plants that can Inhibit Dengue Infection